雷帕霉素机制靶点抑制剂与肾移植受者的疫苗反应
这项前瞻性观察研究比较了接受mTOR抑制剂为基础与标准免疫抑制的肾移植受者对新冠疫苗的体液和细胞免疫应答,并在小鼠中验证机制,随后将低/无应答者随机切换为西罗莫司。mTOR抑制剂组初种疫苗后IFNγ T细胞反应增强12倍,但短期切换策略未改善加强针对病毒的中和比例和T细胞反应。
要点
- 接受mTOR抑制剂为基础的肾移植受者初种新冠疫苗后IFNγ T细胞反应较标准免疫抑制组增强12倍(520 vs 43 斑点形成单位/10^6细胞,P<0.001)。
- mTOR抑制剂组CD4+和CD8+功能性记忆T细胞频率均高于标准治疗组,CD4+特异性T细胞频率也高于健康同住者。
- 将低/无应答者从麦考酚酸切换为西罗莫司4周后加强接种,未显著改善病毒中和比例或T细胞反应。
核心结论
- mTOR抑制与肾移植受者T细胞记忆形成改善相关,但短期将麦考酚酸切换为西罗莫司的策略未能重现该效应。
研究设计与样本
- 前瞻性观察研究,比较接受mTOR抑制剂为基础(mTOR抑制剂+麦考酚酸+泼尼松龙,n=15)与标准治疗(他克莫司+麦考酚酸+泼尼松龙,n=40)免疫抑制的肾移植受者及健康同住者(n=71)对新冠初种疫苗(ChAdOx1或BNT162b2)的体液和细胞免疫应答,并在小鼠中验证机制。
- 随后将接受标准免疫抑制的低/无应答肾移植受者(N=54)按1:1随机分为切换组(麦考酚酸换为西罗莫司)和继续标准治疗组,4周后接种新冠加强针,以免疫增强为主要结局。
主要发现
- mTOR抑制剂组初种疫苗后IFNγ T细胞反应较标准治疗组增强12倍(520 vs 43 斑点形成单位/10^6细胞,P<0.001)。
- mTOR抑制剂组功能性记忆T细胞频率在CD4+(0.20% vs 0.05%,P<0.001)和CD8+(0.35% vs 0.07%,P=0.006)均高于标准治疗组,且mTOR抑制剂组新冠病毒特异性CD4+ T细胞频率高于健康同住者(1.17% vs 0.48%,P=0.03)。
- 小鼠中西罗莫司治疗增强了针对同源和Omicron特异性加强疫苗的回忆性和新发T细胞反应。
- 切换组与对照组达到保护性病毒中和的比例无显著差异(10/25 [40%] vs 9/21 [43%],P=0.85),T细胞反应也无显著差异(P=0.89)。
局限性
- mTOR抑制改善T细胞记忆形成的效应未能通过短期将麦考酚酸切换为西罗莫司的策略重现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
KEY POINTS: Mechanistic target of rapamycin (mTOR) inhibitor–based immunosuppression was associated with an improved T-cell response to vaccination in kidney transplant recipients. Mice treated with an mTOR inhibitor exhibited improved T-cell responses to booster vaccination. Switching low and nonresponder kidney transplant recipients to an mTOR inhibitor did not improve T-cell response to a booster vaccination. BACKGROUND: Failure to develop protective immunity in response to vaccination is common among kidney transplant recipients, rendering them susceptible to severe infection. Novel strategies are required. Here, we investigated the potential of mechanistic target of rapamycin (mTOR) inhibitors to improve vaccine responses. METHODS: Humoral and cellular responses to primary coronavirus disease 2019 (COVID-19) vaccination (ChAdOx1 or BNT162b2) were assessed for kidney transplant recipients receiving mTOR inhibitor–based (mTOR inhibitor, mycophenolate, prednisolone, n=15) and standard-of-care (tacrolimus, mycophenolate, prednisolone, n=40) immunosuppression, and healthy cohabitants (n=71), in a prospective observational study. Findings were validated and mechanisms explored in mice. Low/nonresponding kidney transplant recipients receiving standard-of-care immunosuppression (N=54) were then randomized 1:1 to switch from mycophenolate to sirolimus or remain on standard of care for 4 weeks before receiving COVID-19 booster vaccination. Augmentation of immunity to COVID-19 was assessed as the primary outcome measure. RESULTS: A 12-fold greater IFNγ T-cell response to primary vaccination was observed in kidney transplant recipients receiving mTOR inhibitor–based versus standard-of-care immunosuppression (520 versus 43 spot-forming units/106 cells, P < 0.001). A greater frequency of functional memory T cells in the mTOR inhibitor group was observed for both the CD4+ (0.20% versus 0.05%, P < 0.001) and CD8+ (0.35% versus 0.07%, P = 0.006) compartments by flow cytometry, and kidney transplant recipients receiving mTOR inhibitor–based immunosuppression produced greater frequencies of severe acute respiratory syndrome coronavirus 2–specific CD4+ T cells than healthy cohabitants (1.17% versus 0.48%, P = 0.03). In mice, sirolimus treatment enhanced both recall and de novo T-cell responses to homologous and Omicron-specific booster vaccines. Switch from mycophenolate to sirolimus was well tolerated; however, no significant difference was observed in the proportion of kidney transplant recipients in the intervention and control arms that achieved protective virus neutralization (10/25 [40%] versus 9/21 [43%], respectively, P = 0.85) nor in T-cell response to vaccination (P = 0.89). CONCLUSIONS: mTOR inhibition was associated with improved T-cell memory formation in kidney transplant recipients; however, this effect was not reproduced by a short-term mycophenolate to sirolimus switch strategy. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER:: Australian New Zealand Clinical Trials Registry, ACTRN12621001412820.
引用
- Perkins GB, Tunbridge MJ, Chai CS, et al. Mechanistic Target of Rapamycin Inhibitors and Vaccine Response in Kidney Transplant Recipients. J Am Soc Nephrol. 2025. PMID: 40403135. doi:10.1681/ASN.0000000716
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。